Despite successful treatment of many cancer patients with immune checkpoint inhibitors, the overall response rate of the therapy is low.53 Fostering a CD8+ T cell-rich tumor environment may enhance the responsiveness of immune checkpoint inhibitors. Here, CD8A is linked to cancer.